Table 1.
Baseline characteristics and demographics of the combined SUSTAIN 6 and PIONEER 6 population
| Semaglutide | Placebo | Total | |
|---|---|---|---|
| n = 3239 | n = 3241 | N = 6480 | |
| Baseline characteristics, mean (SD) (except where n [%]) | |||
| Age, years | 65.3 (7.2) | 65.5 (7.4) | 65.4 (7.3) |
| Female, n (%) | 1142 (35.3) | 1160 (35.8) | 2302 (35.5) |
| Diabetes duration, years | 14.4 (8.4) | 14.3 (8.3) | 14.4 (8.3) |
| BMI, kg/m2 | 32.5 (6.4) | 32.5 (6.3) | 32.5 (6.4) |
| HbA1c, % | 8.4 (1.5) | 8.4 (1.6) | 8.4 (1.6) |
| SBP, mmHg | 135.7 (17.5) | 135.5 (17.2) | 135.6 (17.4) |
| DBP, mmHg | 76.6 (10.1) | 76.5 (10.0) | 76.6 (10.0) |
| Total cholesterol, mmol/L (geometric mean [CoV]) | 4.1 (26.9) | 4.1 (26.5) | 4.1 (26.7) |
| Current smoker, n (%) | 388 (12.0) | 367 (11.3) | 755 (11.7) |
| CVD, n (%) | |||
| Prior MI | 1090 (33.7) | 1131 (34.9) | 2221 (34.3) |
| Prior stroke or TIA | 499 (15.4) | 522 (16.1) | 1021 (15.8) |
| Prior arterial revascularization | 1427 (44.1) | 1489 (45.9) | 2916 (45.0) |
| ≥50% stenosis on angiography | 991 (30.6) | 1050 (32.4) | 2041 (31.5) |
| History of symptomatic coronary heart disease | 606 (18.7) | 611 (18.9) | 1217 (18.8) |
| Asymptomatic cardiac ischaemia | 172 (5.3) | 163 (5.0) | 335 (5.2) |
| HF (NYHA Class II–III) | 473 (14.6) | 488 (15.1) | 961 (14.8) |
| CKD (eGFR <60 mL/min/1.73 m2) | 849 (26.2) | 844 (26.0) | 1693 (26.1) |
| CV risk factors, n (%) | |||
| Microalbuminuria or proteinuria | 309 (9.5) | 314 (9.7) | 623 (9.6) |
| Hypertension and left ventricular hypertrophy | 204 (6.3) | 185 (5.7) | 389 (6.0) |
| Left ventricular systolic or diastolic dysfunction† | 134 (4.1) | 127 (3.9) | 261 (4.0) |
| Ankle/brachial index <0.9 | 59 (1.8) | 56 (1.7) | 115 (1.8) |
Abbreviations: BMI, body mass index; CKD, chronic kidney disease; CoV, coefficient of variation; CV, cardiovascular; CVD, cardiovascular disease; DBP, diastolic blood pressure; eGFR, estimated glomerular filtration rate; HF, heart failure; MI, myocardial infarction; NYHA, New York Heart Association; SBP, systolic blood pressure; SD, standard deviation; TIA, transient ischaemic attack.
†
Dysfunction was determined from imaging by the investigators according to local procedures. Data were combined for semaglutide and placebo treatment groups in SUSTAIN 6 and PIONEER 6.